Objectives

AUTHOR=Guo Rui , Meng Xiangxi , Wang Fei , Yu Jiangyuan , Xie Qing , Zhao Wei , Zhu Lin , Kung Hank F. , Yang Zhi , Li Nan TITLE=68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases JOURNAL=Frontiers in Oncology VOLUME=11 YEAR=2021 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.766851 DOI=10.3389/fonc.2021.766851 ISSN=2234-943X ABSTRACT=Objectives

⁶⁸Ga-P15-041 (⁶⁸Ga-HBED-CC-BP) is a novel bone-seeking PET radiotracer, which can be readily prepared by using a simple kit formulation and an in-house ⁶⁸Ga/⁶⁸Ge generator. The aim of this study is to assess the potential human application of ⁶⁸Ga-P15-041 for clinical PET/CT imaging and to compare its efficacy to detect bone metastases of different cancers with ⁹⁹mTc-MDP whole-body bone scintigraphy (WBBS).

Methods

Initial kinetic study using Patlak analysis and parametric maps were performed in five histopathologically proven cancer patients (three males, two females) using ⁶⁸Ga-P15-041 PET/CT scan only. Another group of 51 histopathologically proven cancer patients (22 males, 29 females) underwent both ⁹⁹mTc-MDP WBBS and ⁶⁸Ga-P15-041 PET/CT scans within a week, sequentially. Using either pathology examination or follow-up CT or MRI scans as the gold standard, the diagnostic efficacy and receiver operating characteristic curve (ROC) of the two methods in identifying bone metastases were compared (p <0.05, statistically significant).

Results

Fifty-one patients were imaged, and 174 bone metastatic sites were identified. ⁶⁸Ga-P15-041 PET/CT and ⁹⁹mTc-MDP WBBS detected 162 and 81 metastases, respectively. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of ⁶⁸Ga-P15-041 PET/CT and ⁹⁹mTc-MDP WBBS were 93.1% vs 81.8%, 89.8% vs 90.7%, 77.5% vs 69.2%, 97.2% vs 93.4% and 90.7% vs 88.4%, respectively. Our results showed that the mean of SUVmax was significantly higher in metastases than that in benign lesions, 15.1 ± 6.9 vs. 5.6 ± 1.3 (P <0.001). Using SUVmax = 7.6 as the cut-off value by PET/CT, it was possible to predict the occurrence of metastases (AUC = 0.976; P <0.001; 95% CI: 0.946–0.999). However, it was impossible to distinguish osteoblastic bone metastases from osteolytic bone lesions. Parametric maps based on Patlak analysis provided excellent images and highly valuable quantitative information.

Conclusions

⁶⁸Ga-P15-041 PET/CT, offering a rapid bone scan and high contrast images in minutes, is superior to the current method of choice in detecting bone metastases. It is reasonable to suggest that ⁶⁸Ga-P15-041 PET/CT could become a valuable routine nuclear medicine procedure in providing excellent images for detecting bone metastases in cancer patients. ⁶⁸Ga-P15-041 could become a valuable addition expanding the collection of ⁶⁸Ga-based routine nuclear medicine procedures where ¹⁸F fluoride is not currently available.